Beardsworth has selected OmniComm Systems’ (OmniComm) TrialMaster EDC solution for conducting a Phase II vaccine study. The three-year, ten-site study is planning to enroll 340 subjects.
OmniComm and Beardsworth plan electronic imports of data to TrialMaster EDC, utilising OmniComm’s native, template matching subsystem. Electronic exports from TrialMaster EDC to Beardsworth’s BNet portal will be achieved utilising OmniComm’s new RESTful Web Services, Application Programming Interface (API).
Michael O’Brien, president and CEO of Beardsworth, said: After a careful selection process, we chose OmniComm Systems to be our preferred EDC provider.”
Stephen Johnson, COO of OmniComm, said: We look forward to working with Beardsworth on their next study and welcome them to our very successful CRO preferred program. We are pleased that OmniComm’s electronic data capture solution, TrialMaster, was chosen to capture and process the clinical trial data of this exciting vaccine study.
“TrialMaster will enable Beardsworth to confidently offer their clients an extensible, eClinical solution that will complement the outstanding services which have made their company a success.